Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Any predictions
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1207)
•••
Comment by Duster340on Jan 04, 2024 12:23pm
297 Views
Post# 35810690

RE:RE:RE:RE:RE:RE:Any predictions

RE:RE:RE:RE:RE:RE:Any predictions
MrMugsy wrote: Oh ... we'll retest $1.23.

Just think back to the action during the last P2.

This time - were are much more risk-reduced ... and ... we're looking at patents of 15-20 years.

Don't forget ... we're likely to see new patents on top of the reformulation patents that pertain specifically to regimen and regimen control (both acute and chronic).

Should chronic not work - I'm still banking on a minimum of a chronic flare-up drug.

-------------------

On the topic of warrants ... the share price really needs to jump if we're going to see $6.5 MM in the bank from the warrant offering (that's all I'm getting at).


i agree longer term the stock should do good. i was on the ride last P2. i was just talking about how high it will go on the jan/18th news before it peaks and has a bit of a pullback. like we seen when it ran up in november to $1.23 then came back to around 70 cents. although the next pullback may not be as much. if you can time that right there is extra money to be made. buy near the lows, sell near the peaks. does not always work out but so far i have timed this one very good.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities